Rational design of potent human transthyretin amyloid disease inhibitors
about
Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitorsTissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue cultureStructural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemiaMechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisEvolutionary Limitation and Opportunities for Developing tRNA Synthetase Inhibitors with 5-Binding-Mode ClassificationPhotoaffinity labeling of plasma proteinsChemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosisThe delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiologyMechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenolsHuman-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteinsToward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis InhibitorsToward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural AnalysisA Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and CytotoxicityChemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasmaStructure of trans -Resveratrol in Complex with the Cardiac Regulatory Protein Troponin CCrystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding SitesAromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent ConjugateTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeBifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensorsFluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learnStilbene Vinyl Sulfonamides as Fluorogenic Sensors of and Traceless Covalent Kinetic Stabilizers of Transthyretin That Prevent AmyloidogenesisX-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitorsStructural evidence for asymmetric ligand binding to transthyretinSynthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR)Amyloidosis: a convoluted storyHuman apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensityTargeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseTetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin TetramerDe novo design of helical bundles as models for understanding protein folding and function.Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.Identifying protein stabilizing ligands using GroEL.Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methodsOptimal identification of semi-rigid domains in macromolecules from molecular dynamics simulation.Diverse clinical compounds alter the quaternary structure and inhibit the activity of an essential enzymeGenistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosisStructure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidosesTransthyretin amyloidosis: a tale of weak interactions.A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.
P2860
Q24296622-C3940BE1-5A05-4523-A3F3-80B0B1AAE7B1Q24626477-19E10776-4FDA-44FE-8B72-26784CF45E90Q24671472-F5663A34-FCBC-4591-932E-2FC6FF087834Q26764754-E2EE6DDC-9F07-4102-B26A-7B0A6F8A4442Q26775728-0A60DE4D-C7AF-40F2-A581-8043CFA24F7AQ26829329-55335F5A-8A15-4281-93A0-04AC45F93332Q27004511-6508C85D-7AAB-49E5-8DAF-514A3A7D610FQ27015793-BFF5197B-A00E-49B0-BA42-5458A3C64340Q27647277-13FD31D7-72D7-4840-8B3C-4E0519DCEDDBQ27649069-8F1C5C87-CFC4-4D59-A2C5-B833CEBB01BDQ27652272-672A6FA3-7EF7-4A2F-9560-3AB495180322Q27653350-2010666C-A05D-46D7-B7B7-8B77D9D29F24Q27653642-556AD973-766A-43BD-B60D-B51C5F979DD3Q27656578-23F4A3A9-9AC4-46E3-8EB7-4345986491BAQ27658823-2FE3AD6E-1360-4802-B593-AAA07D797CBFQ27659009-1FBAB5B4-04EE-4651-9CA7-A420973FA404Q27666558-F1B03C66-21BF-4890-BEDE-6C4545003301Q27673044-F38F86F7-E437-4A25-BFB5-44787A1B0398Q27675997-0C430061-D7F5-468B-9B70-45951BB486D3Q27679360-7B8E0025-8F33-4C1E-8EDA-585ED5ACEAA1Q27679824-F47C05AF-A167-4C1B-BD7D-5202A5E7E04CQ27680199-029DCABF-0A0F-44A6-AF4C-E4753B908171Q27680500-07632A6E-5F35-4990-95C7-0D9D34E9A570Q27701718-9D353580-C96F-4437-8A15-AAE90DCD3109Q27701741-94DA5FF7-17B6-447E-99D9-0E0CE213CCA7Q27704552-8040E158-8AAE-4266-91DD-AB86E18C7E46Q28215995-7FB16B46-F9F9-49D0-9205-AA644B7DCD5DQ28482893-97E4D49D-F4B3-4F75-BDF8-348903A6D098Q28539839-B3BF67DC-0A57-4FCB-B983-81C2DDC00D78Q28551432-6D7AA52C-417A-474D-8DCB-FBCFDBDE15E4Q30327505-AD6ADAD3-E766-49CC-94D4-E5DC04C46507Q30370141-8DCD7CD4-30E1-4486-84DA-DA5B6A6F310FQ33508608-D5F33035-FEB5-4C3D-B940-805C6242241CQ33541145-86924F21-9B14-4E06-BA29-56D61313AFFFQ33586097-CCF3EC9D-5DBE-4557-A3A7-C4E0925184D0Q33877421-D7ACD6F9-CA18-4E0F-9B2B-DEC5B99FA8FEQ34078348-A377E763-DE66-408B-BE76-D92F4F872255Q34096983-8A9B7BE5-7D88-4170-A3CC-B32115973236Q34286109-0C3D8762-B0EE-4A06-92B8-199B1C40169BQ34300151-0EA484CD-65E8-4DCE-AA4B-7B35EFE68804
P2860
Rational design of potent human transthyretin amyloid disease inhibitors
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rational design of potent human transthyretin amyloid disease inhibitors
@ast
Rational design of potent human transthyretin amyloid disease inhibitors
@en
Rational design of potent human transthyretin amyloid disease inhibitors
@nl
type
label
Rational design of potent human transthyretin amyloid disease inhibitors
@ast
Rational design of potent human transthyretin amyloid disease inhibitors
@en
Rational design of potent human transthyretin amyloid disease inhibitors
@nl
prefLabel
Rational design of potent human transthyretin amyloid disease inhibitors
@ast
Rational design of potent human transthyretin amyloid disease inhibitors
@en
Rational design of potent human transthyretin amyloid disease inhibitors
@nl
P2093
P3181
P356
P1476
Rational design of potent human transthyretin amyloid disease inhibitors
@en
P2093
H M Petrassi
J C Sacchettini
T Klabunde
P304
P3181
P356
10.1038/74082
P577
2000-04-01T00:00:00Z